紫杉醇联合顺铂治疗46例晚期头颈部肿瘤的临床观察

Clinical Observation of 46 Patients with Advanced Head and Neck Neoplasms Treated with Paclitaxel Combined with Cisplatin

目的观察紫杉醇联合顺铂治疗晚期头颈部肿瘤的疗效及毒副反应。方法对46例晚期头颈部肿瘤进行化疗，方案为紫杉醇135mg／m^2，d1；顺铂25～40mg／m^2，d2-4。21d为1周期，治疗2周期后评价疗效及毒副反应。结果46例均可评价疗效，共完成周期数为160个，完全缓解（CIR）2例，部分缓解（PR）14例，稳定（SD）18例，进展（PD）12例，总有效率（CR＋PR）34．8％，疾病控制率（CR＋PR＋SD）73．9％，中位疾病进展时间6．7个月，巾位生存期为22．3个月（2．0～52．5个月）。主要毒副反应为骨髓抑制、胃肠道反应。结论紫杉醇联合顺铂治疗晚期头颈部肿瘤疗效较好，毒副反应可耐受。

Objective To study the efficacy and toxieities of paclitaxel combined with cisplatin in the treatment of patients with advanced head and neck neoplasms. Methods Forty-six patients with advanced head and neck neoplasms were treated with paelitaxel 135 mg/m^2 on day 1 , cisplatin 25-40 mg/m^2 on days 2- 4. The chemotherapy be repeated every 3 weeks, the efficacy and toxicities were reviewed after 2 cycles of chemotherapy. Results All the 46 patients were evaluahle for response. CR 2 cases, PR 14 cases, SD 18 cases, and PD 12 cases. The overall response rate was 34.8% and the disease control rate was 73.9%. The median time to progression was 6.7 months, and the median survival time was 22.3 months. The main toxicitics included myelosuppression, gastrointestinal toxicities. Conclusion Paclitaxel combined with cisplatin is effective in the treatment of patients with advanced head and neck neoplasms, the toxicities are tolerable.